.jpg "HCPH-Riverside-0708-1870×125-Spa (1)")
Eli Lilly formally broke ground Monday on a $6.5 billion pharmaceutical manufacturing campus in northeast Houston. The Eli Lilly Houston plant is expected to create thousands of construction jobs and strengthen the region’s growing life sciences sector.
The ceremony took place nearly one year after Lilly announced the project. Early construction work began during the summer.
$6.5 Billion Eli Lilly Houston Plant Takes Shape
The 236-acre campus will rise at Generation Park near Beltway 8. The master-planned development sits about 10 miles east of George Bush Intercontinental Airport.
Lilly selected Houston after reviewing more than 300 potential locations. The company cited the region’s workforce, infrastructure, transportation access and business environment.
State filings outline at least six buildings covering more than 800,000 square feet. However, plans may change as the project moves through construction.
One registered construction package covers a 341,505-square-foot manufacturing building. The Texas Department of Licensing and Regulation lists November 2027 as its expected completion date.
That timeline does not represent the entire campus. Lilly has said the full facility remains on track to begin operations by 2030.
Houston Facility Will Produce Medicine Ingredients
The campus will manufacture active pharmaceutical ingredients, commonly called APIs. These substances provide the therapeutic effect in medications.
The facility will focus on small-molecule synthetic medicines. Lilly uses these compounds across cardiometabolic health, cancer care, immunology and neuroscience.
The Houston site will also help Lilly expand production of Foundayo, the brand name for orforglipron. The oral GLP-1 medication received federal approval in April 2026.
Unlike injectable GLP-1 treatments, Foundayo comes as a once-daily tablet. The Food and Drug Administration approved it for long-term weight management in qualifying adults.
Lilly previously said the Houston campus would help manufacture orforglipron at scale. The added capacity could support growing demand while expanding domestic medicine production.
Thousands of Jobs Expected During Construction
Lilly expects the project to generate about 4,000 construction jobs. Once operational, the campus should employ 615 people.
Permanent positions will include engineers, scientists, laboratory technicians and operations workers. The company has described them as high-wage jobs requiring specialized skills.
Lilly also plans to work with Texas colleges and universities on workforce development. Those partnerships could create training opportunities for students interested in science, manufacturing and technology careers.
The campus will use automated systems, artificial intelligence and advanced data analysis. These tools will help manage production and monitor product quality.
Texas approved the project for assistance through the Jobs, Energy, Technology and Innovation program. The state also extended Lilly a $5.5 million Texas Enterprise Fund grant, according to the governor’s office.
Major Investment for Houston’s Life Sciences Sector
State officials have called the project the largest active pharmaceutical ingredient manufacturing investment in Texas to date. The campus also ranks among Houston’s largest recent corporate developments.
The investment adds pharmaceutical manufacturing to a regional economy known for health care, energy, logistics and aerospace. Generation Park’s access to highways and the airport could also support Lilly’s supply chain.
However, the campus will take several years to complete. Hiring for many permanent positions will likely occur closer to the start of operations.
Houston-area residents can follow Lilly’s career announcements and local workforce programs as construction advances. The project could provide new pathways into pharmaceutical manufacturing while expanding the region’s role in producing medicines within the United States.